Next 10 |
CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President, wil...
Shares of left-for-dead Unum Therapeutics surged nearly 400% on its acquisition of privately held Kiq Bio and a concurrent $104.4 million capital infusion. Kiq provided Unum with one clinical candidate (PLX9486) for three indications. Although the company appears to be trading at ...
Unum Therapeutics (UMRX) has changed its name to Cogent Biosciences, and will commence trading under a new ticker 'COGT', effective tomorrow. The company says it remains on track to advance its lead asset, PLX9486 as a single agent in advanced systemic mastocytosis patients in 1H of next year...
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients Company on track to advance CGT9486 into ...
Gainers: Corcept Therapeutics (NASDAQ: CORT ) +35% . More news on: Corcept Therapeutics Incorporated, Vera Bradley, Inc., NanoViricides, Inc., Stocks on the move, , Read more ...
Unum Therapeutics' ( UMRX -0.3% ) BOXR cell therapy platform and BOXR lead programs, to develop novel T cell therapies for the treatment of solid tumors, were acquired by SOTIO, a clinical stage immuno-oncology company owned by PPF Group. More news on: Unum Therapeutics Inc., He...
SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies Lead progra...
CAMBRIDGE, Mass. , Aug. 31, 2020 /PRNewswire/ -- Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company focused on developing novel, best-in-class precision kinase inhibitors for a range of patients living with cancer and other unmet medical needs, announced today the sal...
Venrock Healthcare Capital Partners discloses the purchase 0.451M shares of Unum Therapeutics (NASDAQ: UMRX ) between Aug. 14 and Aug. 18 at average price of $2.52/share. More news on: Unum Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...
Momenta Pharmaceuticals (NASDAQ: MNTA ) +69% on J&J acquisition . More news on: Momenta Pharmaceuticals, Inc., Hudson Ltd., LightInTheBox Holding Co., Ltd., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President, wil...
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients Company on track to advance CGT9486 into ...
SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies Lead progra...